Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + APF in Locally Advanced Head and Neck Tumors
NCT05758389Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2022
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Nanjing Drum-Tower Hospital. Started Apr 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05758389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05758389.